Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study
Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the...
Saved in:
| Published in: | PLoS medicine Vol. 17; no. 5; p. e1003101 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Public Library of Science
14.05.2020
Public Library of Science (PLoS) |
| Subjects: | |
| ISSN: | 1549-1676, 1549-1277, 1549-1676 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population.
PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23-2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04-2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67-0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period.
Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. |
|---|---|
| AbstractList | Background Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. Methods and findings PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23-2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04-2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm.sup.3 increase, 95% CI 0.67-0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period. Conclusions Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23-2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04-2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67-0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period. Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. Background Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. Methods and findings PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003–2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999–2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23–2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04–2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67–0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period. Conclusions Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. Background Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population. Methods and findings PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003–2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999–2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23–2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04–2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67–0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period. Conclusions Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. Casper Rokx and colleagues study the risk of recurrent venous thromboembolism in people with HIV infection. Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population.BACKGROUNDMultiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of recurrent VTE in this population are lacking, although this question is more important for clinical practice. This study aims to estimate the risk of recurrent VTE in PWH compared to controls and to identify risk factors for recurrence within this population.PWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23-2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04-2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67-0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period.METHODS AND FINDINGSPWH with a first VTE were derived from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort (2003-2015), a nationwide ongoing cohort following up PWH in care in the Netherlands. Uninfected controls were derived from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) follow-up study (1999-2003), a cohort of patients with a first VTE who initially participated in a case-control study in the Netherlands who were followed up for recurrent VTE. Selection was limited to persons with an index VTE suffering from deep vein thrombosis in the lower limbs and/or pulmonary embolism (PE). Participants were followed from withdrawal of anticoagulation to VTE recurrence, loss to follow-up, death, or end of study. We estimated incidence rates, cumulative incidence (accounting for competing risk of death) and hazard ratios (HRs) using Cox proportional hazards regression, adjusting for age, sex, and whether the index event was provoked or unprovoked. When analyzing risk factors among PWH, the main focus of analysis was the role of immune markers (cluster of differentiation 4 [CD4]+ T-cell count). There were 153 PWH (82% men, median 48 years) and 4,005 uninfected controls (45% men, median 49 years) with a first VTE (71% unprovoked in PWH, 34% unprovoked in controls) available for analysis. With 40 VTE recurrences during 774 person-years of follow-up (PYFU) in PWH and 635 VTE recurrences during 20,215 PYFU in controls, the incidence rates were 5.2 and 3.1 per 100 PYFU (HR: 1.70, 95% CI 1.23-2.36, p = 0.003). VTE consistently recurred more frequently per 100 PYFU in PWH in all predefined subgroups of men (5.6 versus 4.8), women (3.6 versus 1.9), and unprovoked (6.0 versus 5.2) or provoked (3.1 versus 2.1) first VTE. After adjustment, the VTE recurrence risk was higher in PWH compared to controls in the first year after anticoagulant discontinuation (HR: 1.67, 95% CI 1.04-2.70, p = 0.03) with higher cumulative incidences in PWH at 1 year (12.5% versus 5.6%) and 5 years (23.4% versus 15.3%) of follow-up. VTE recurred less frequently in PWH who were more immunodeficient at the first VTE, marked by a better CD4+ T-cell recovery on antiretroviral therapy and during anticoagulant therapy for the first VTE (adjusted HR: 0.81 per 100 cells/mm3 increase, 95% CI 0.67-0.97, p = 0.02). Sensitivity analyses addressing potential sources of bias confirmed our principal analyses. The main study limitations are that VTEs were adjudicated differently in the cohorts and that diagnostic practices changed during the 20-year study period.Overall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE.CONCLUSIONSOverall, the risk of recurrent VTE was elevated in PWH compared to controls. Among PWH, recurrence risk appeared to decrease with greater CD4+ T-cell recovery after a first VTE. This is relevant when deciding to (dis)continue anticoagulant therapy in PWH with otherwise unprovoked first VTE. |
| Audience | Academic |
| Author | Borjas Howard, Jaime F. Tichelaar, Vladimir Rokx, Casper Meijer, Karina Reiss, Peter Rijnders, Bart J. A. Bierman, Wouter Pieterman, Elise D. Lijfering, Willem M. Cannegieter, Suzanne C. Wit, Ferdinand W. Smit, Colette |
| AuthorAffiliation | 2 University of Groningen, University Medical Centre Groningen, Department of Haematology, Groningen, the Netherlands 4 Department of Global Health and Division of Infectious Diseases, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands 1 Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Section of Infectious Diseases, Rotterdam, the Netherlands Instituto de Salud Carlos III, SPAIN 3 HIV Monitoring Foundation, Amsterdam, the Netherlands 6 University of Groningen, University Medical Centre Groningen, Department of Internal Medicine, Infectious Diseases Service, Groningen, the Netherlands 5 Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, the Netherlands |
| AuthorAffiliation_xml | – name: Instituto de Salud Carlos III, SPAIN – name: 1 Erasmus MC, University Medical Centre Rotterdam, Department of Internal Medicine, Section of Infectious Diseases, Rotterdam, the Netherlands – name: 3 HIV Monitoring Foundation, Amsterdam, the Netherlands – name: 5 Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, the Netherlands – name: 4 Department of Global Health and Division of Infectious Diseases, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands – name: 2 University of Groningen, University Medical Centre Groningen, Department of Haematology, Groningen, the Netherlands – name: 6 University of Groningen, University Medical Centre Groningen, Department of Internal Medicine, Infectious Diseases Service, Groningen, the Netherlands |
| Author_xml | – sequence: 1 givenname: Casper surname: Rokx fullname: Rokx, Casper – sequence: 2 givenname: Jaime F. orcidid: 0000-0001-6634-746X surname: Borjas Howard fullname: Borjas Howard, Jaime F. – sequence: 3 givenname: Colette surname: Smit fullname: Smit, Colette – sequence: 4 givenname: Ferdinand W. surname: Wit fullname: Wit, Ferdinand W. – sequence: 5 givenname: Elise D. surname: Pieterman fullname: Pieterman, Elise D. – sequence: 6 givenname: Peter orcidid: 0000-0001-7896-6428 surname: Reiss fullname: Reiss, Peter – sequence: 7 givenname: Suzanne C. orcidid: 0000-0003-4707-2303 surname: Cannegieter fullname: Cannegieter, Suzanne C. – sequence: 8 givenname: Willem M. surname: Lijfering fullname: Lijfering, Willem M. – sequence: 9 givenname: Karina orcidid: 0000-0001-9447-0465 surname: Meijer fullname: Meijer, Karina – sequence: 10 givenname: Wouter orcidid: 0000-0002-4389-9365 surname: Bierman fullname: Bierman, Wouter – sequence: 11 givenname: Vladimir orcidid: 0000-0001-7907-7032 surname: Tichelaar fullname: Tichelaar, Vladimir – sequence: 12 givenname: Bart J. A. surname: Rijnders fullname: Rijnders, Bart J. A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32407386$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVk-9r1DAYx4tM3A_9D0QLguiLO5M0bdq9EI6h7mA4mLq3IU2eXnO2zS1JN_ffm9v15DoOUUJoePp5vnny_DiODjrTQRS9xGiKE4Y_LE1vO9FMVy2oKUYowQg_iY5wSosJzlh2sHM-jI6dWyJEClSgZ9FhQihiSZ4dReWVdj9jU8UWZG8tdD6-hc70Lva1NW1pIOxGuzbWXbwSXgfCxXfa1_H5_DoYK5Bem-40nsWdWJ_utIJYmtpYHzvfq_vn0dNKNA5eDN-T6MfnT9_PzicXl1_mZ7OLiWQZ9RNGZKJKUhGJAZSqSpkzBqysKM5UmhY5lSAAScWEYLkkipUUJ1kuq4oqWrLkJHq90V01xvEhPY4TSijNUsZwIOYbQhmx5CurW2HvuRGaPxiMXXBhvZYNcJnmCLNCEEElLQEJgopSIZAsZ1SRtdbH4ba-DBWQIS9WNCPR8Z9O13xhbjkjIZ40CQLvBgFrbnpwnrfaSWga0UHIf4gbhZWyPA3om0fo_tcN1EKEB4TKmHCvXIvyWZaQIkVpXgRqsodaQAchyNBhlQ7mET_dw4eloNVyr8P7kUNgPPzyC9E7x-ffrv6D_frv7OX1mH27w9YgGl870_Tr_nRj8NVuFf-UbzsgATjdANIa5yxUXGr_0OchDbrhGPH1NG4LwtfTyIdpDM70kfNW_69uvwHdDzjH |
| CitedBy_id | crossref_primary_10_2147_IJGM_S359893 crossref_primary_10_1186_s12959_024_00627_2 crossref_primary_10_1055_s_0042_1754391 crossref_primary_10_1016_S2352_3018_21_00148_X crossref_primary_10_1080_09537104_2021_2019695 crossref_primary_10_4102_sajhivmed_v22i1_1253 crossref_primary_10_1161_ATVBAHA_122_318232 crossref_primary_10_1007_s00580_025_03657_y crossref_primary_10_1111_hiv_13309 crossref_primary_10_1002_hsr2_1085 crossref_primary_10_1007_s40520_020_01775_x crossref_primary_10_1016_j_heliyon_2023_e16519 crossref_primary_10_1055_a_2574_8874 crossref_primary_10_3390_cells11040690 crossref_primary_10_1038_s41598_022_10330_9 crossref_primary_10_1136_bcr_2021_244983 crossref_primary_10_1016_j_revmed_2023_01_006 crossref_primary_10_1016_j_ccm_2024_10_014 crossref_primary_10_1097_QAI_0000000000003339 crossref_primary_10_3390_jcm10040877 crossref_primary_10_3390_pathogens14080816 crossref_primary_10_3892_br_2025_2000 |
| Cites_doi | 10.1093/cid/cit780 10.1160/TH11-09-0611 10.1016/j.chest.2015.11.026 10.1055/s-0032-1328887 10.1111/jth.13336 10.1111/j.1468-1293.2010.00869.x 10.1002/rth2.12101 10.1111/bjh.14551 10.1111/jth.12043 10.1111/j.1365-2796.2011.02473.x 10.1186/1742-6405-7-9 10.1001/archinternmed.2007.5 10.1016/S2352-3018(18)30333-3 10.1136/bmjopen-2018-022516 10.1378/chest.11-2301 10.1136/bmj.f3368 10.1089/apc.2009.0173 10.1371/journal.pmed.1002883 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 Public Library of Science 2020 Rokx et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 Rokx et al 2020 Rokx et al |
| Copyright_xml | – notice: COPYRIGHT 2020 Public Library of Science – notice: 2020 Rokx et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 Rokx et al 2020 Rokx et al |
| CorporateAuthor | on behalf of the ATHENA observational HIV cohort ATHENA observational HIV cohort |
| CorporateAuthor_xml | – name: on behalf of the ATHENA observational HIV cohort – name: ATHENA observational HIV cohort |
| DBID | AAYXX CITATION NPM IOV ISN ISR 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA CZK |
| DOI | 10.1371/journal.pmed.1003101 |
| DatabaseName | CrossRef PubMed Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals PLoS Medicine |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Recurrent venous thromboembolism in HIV |
| EISSN | 1549-1676 |
| ExternalDocumentID | 2424465771 oai_doaj_org_article_c580179a2a4c4be0a209bd0ec7874d21 PMC7224453 A632950589 32407386 10_1371_journal_pmed_1003101 |
| Genre | Journal Article |
| GeographicLocations | Netherlands |
| GeographicLocations_xml | – name: Netherlands |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAUCC AAWOE AAWTL AAYXX ABDBF ABUWG ACCTH ACGFO ACIHN ACPRK ACUHS ADBBV AEAQA AENEX AFFHD AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAIFH BAWUL BBTPI BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IOF IOV IPO ISN ISR ITC KQ8 M1P M48 MK0 O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PV9 RNS RPM RZL SV3 TR2 TUS UKHRP WOW XSB YZZ ~8M 3V. ADRAZ ALIPV BCGST H13 ICW IPNFZ M~E NPM PKN RIG WOQ 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM - AAPBV ABPTK ADACO BBAFP CZK |
| ID | FETCH-LOGICAL-c764t-72c3db2f2c1eeddfbc877e7bf416d55984ceae0cd7aa78c2d7b41368cff4d4b73 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 24 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000558077100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1549-1676 1549-1277 |
| IngestDate | Fri Nov 26 17:52:53 EST 2021 Fri Oct 03 12:50:55 EDT 2025 Tue Nov 04 01:58:26 EST 2025 Thu Oct 02 11:10:32 EDT 2025 Sat Nov 29 14:22:11 EST 2025 Tue Nov 11 07:43:53 EST 2025 Sat Nov 29 11:10:35 EST 2025 Tue Nov 04 18:00:12 EST 2025 Thu Nov 13 14:22:21 EST 2025 Thu Nov 13 14:38:54 EST 2025 Thu Nov 13 14:29:52 EST 2025 Thu May 22 21:04:59 EDT 2025 Wed Feb 19 02:31:23 EST 2025 Sat Nov 29 05:33:55 EST 2025 Tue Nov 18 21:10:24 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c764t-72c3db2f2c1eeddfbc877e7bf416d55984ceae0cd7aa78c2d7b41368cff4d4b73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 I have read the journal's policy and the authors of this manuscript have the following competing interests: CR reports grants from Gilead, Merck, and personal fees from Gilead, ViiV, Janssen-Cilag. JFBH and EDP report no conflicts of interest. YIGVT was employed by the Dutch National Health Institute during analysis and reporting on this study. CS reports grants from Netherlands Ministry of Health, Welfare and Sport, National Institute for Public Health and the Environment, Centre for Infectious Disease Control, during the conduct of the study. FW reports personal fees from Gilead Sciences, personal fees from ViiV Healthcare, outside the submitted work. PR reports independent scientific grant support to his institution from Gilead Sciences, Janssen Pharmaceuticals Inc., Merck & Co., Bristol-Myers Squibb, and ViiV Healthcare; fees to his institution for his participation on scientific advisory boards for Gilead Sciences ViiV Healthcare, Merck & Co., Teva pharmaceutical industries, and on a data safety monitoring committee for Janssen Pharmaceuticals Inc. BR reports grants from Gilead, grants from MSD, nonfinancial support from MSD, nonfinancial support from Gilead, nonfinancial support from BMS, nonfinancial support from Janssen-Cilag, nonfinancial support from ViiV, nonfinancial support from Abbvie, personal fees from Gilead, personal fees from ViiV, personal fees from Great-Lakes pharmaceuticals, outside the submitted work; and financial compensation payed to institution for advisory board participation organized by Gilead, ViiV, BMS, Janssen-Cilag, and MSD. KM received research support from Bayer, Sanquin, and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS, and Aspen; consulting fees from Uniqure (outside the submitted work, all fees go to the institution). WBW reports reimbursement payed to institution for investigator-initiated study from Janssen-Cilag, financial compensation payed to institution for multicenter study by GSK and catering of a symposium by Janssen-Cilag, all outside the submitted work. SCC is a member of the Editorial Board of PLOS Medicine. WML reports no conflicts of interest. Membership of the ATHENA observational HIV cohort is provided in S1 Supplementary Methods. |
| ORCID | 0000-0001-6634-746X 0000-0001-7896-6428 0000-0001-9447-0465 0000-0001-7907-7032 0000-0002-4389-9365 0000-0003-4707-2303 |
| OpenAccessLink | https://doaj.org/article/c580179a2a4c4be0a209bd0ec7874d21 |
| PMID | 32407386 |
| PQID | 2424465771 |
| PQPubID | 1436338 |
| ParticipantIDs | plos_journals_2424465771 doaj_primary_oai_doaj_org_article_c580179a2a4c4be0a209bd0ec7874d21 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7224453 proquest_miscellaneous_2404045785 proquest_journals_2424465771 gale_infotracmisc_A632950589 gale_infotracgeneralonefile_A632950589 gale_infotracacademiconefile_A632950589 gale_incontextgauss_ISR_A632950589 gale_incontextgauss_ISN_A632950589 gale_incontextgauss_IOV_A632950589 gale_healthsolutions_A632950589 pubmed_primary_32407386 crossref_citationtrail_10_1371_journal_pmed_1003101 crossref_primary_10_1371_journal_pmed_1003101 |
| PublicationCentury | 2000 |
| PublicationDate | 20200514 |
| PublicationDateYYYYMMDD | 2020-05-14 |
| PublicationDate_xml | – month: 5 year: 2020 text: 20200514 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PLoS medicine |
| PublicationTitleAlternate | PLoS Med |
| PublicationYear | 2020 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | E Auerbach (pmed.1003101.ref001) 2012; 38 E Jong (pmed.1003101.ref002) 2009; 23 TS Boender (pmed.1003101.ref016) 2018; 8 JF Borjas-Howard (pmed.1003101.ref006) 2017; 110 C Kearon (pmed.1003101.ref020) 2012; 141 LJJ Scheres (pmed.1003101.ref022) 2018; 2 SK Klein (pmed.1003101.ref009) 2005; 63 C Kearon (pmed.1003101.ref014) 2016; 14 JF Timp (pmed.1003101.ref015) 2017; 176 C Kearon (pmed.1003101.ref013) 2016; 149 E Jong (pmed.1003101.ref004) 2010; 7 E Jong (pmed.1003101.ref003) 2010; 104 KJ van Stralen (pmed.1003101.ref018) 2008; 168 G Ocak (pmed.1003101.ref019) 2013; 11 pmed.1003101.ref012 M Schmidt (pmed.1003101.ref005) 2012; 271 JF Timp (pmed.1003101.ref017) 2019; 16 C Dentan (pmed.1003101.ref007) 2014; 58 LD Rasmussen (pmed.1003101.ref010) 2011; 12 JFB Howard (pmed.1003101.ref011) 2019; 6 RS Wiener (pmed.1003101.ref021) 2013; 347 YI Tichelaar (pmed.1003101.ref008) 2012; 107 |
| References_xml | – volume: 63 start-page: 129 issue: 4 year: 2005 ident: pmed.1003101.ref009 article-title: Is chronic HIV infection associated with venous thrombotic disease? A systematic review. publication-title: Neth J Med – volume: 58 start-page: 495 issue: 4 year: 2014 ident: pmed.1003101.ref007 article-title: Active tuberculosis and venous thromboembolism: association according to international classification of diseases, ninth revision hospital discharge diagnosis codes publication-title: Clin Infect Dis doi: 10.1093/cid/cit780 – volume: 107 start-page: 827 issue: 5 year: 2012 ident: pmed.1003101.ref008 article-title: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review publication-title: Thromb Haemost doi: 10.1160/TH11-09-0611 – volume: 149 start-page: 315 issue: 2 year: 2016 ident: pmed.1003101.ref013 article-title: Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. publication-title: Chest doi: 10.1016/j.chest.2015.11.026 – volume: 38 start-page: 830 issue: 8 year: 2012 ident: pmed.1003101.ref001 article-title: Venous and arterial thromboembolic complications associated with HIV infection and highly active antiretroviral therapy. publication-title: Semin Thromb Hemost doi: 10.1055/s-0032-1328887 – volume: 14 start-page: 1480 issue: 7 year: 2016 ident: pmed.1003101.ref014 article-title: Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.13336 – volume: 12 start-page: 202 issue: 4 year: 2011 ident: pmed.1003101.ref010 article-title: HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. publication-title: HIV Med. doi: 10.1111/j.1468-1293.2010.00869.x – volume: 2 start-page: 199 issue: 2 year: 2018 ident: pmed.1003101.ref022 article-title: Current and future burden of venous thrombosis: Not simply predictable publication-title: Res Pract Thromb Haemost doi: 10.1002/rth2.12101 – volume: 176 start-page: 961 issue: 6 year: 2017 ident: pmed.1003101.ref015 article-title: Antibiotic use as a marker of acute infection and risk of first and recurrent venous thrombosis publication-title: Br J Haematol doi: 10.1111/bjh.14551 – volume: 11 start-page: 116 issue: 1 year: 2013 ident: pmed.1003101.ref019 article-title: Risk of venous thrombosis in patients with major illnesses: results from the MEGA study publication-title: J Thromb Haemost doi: 10.1111/jth.12043 – volume: 271 start-page: 608 issue: 6 year: 2012 ident: pmed.1003101.ref005 article-title: Acute infections and venous thromboembolism publication-title: J Intern Med doi: 10.1111/j.1365-2796.2011.02473.x – volume: 7 start-page: 9 year: 2010 ident: pmed.1003101.ref004 article-title: Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir publication-title: AIDS Res Ther doi: 10.1186/1742-6405-7-9 – volume: 168 start-page: 21 issue: 1 year: 2008 ident: pmed.1003101.ref018 article-title: Minor injuries as a risk factor for venous thrombosis publication-title: Arch Intern Med doi: 10.1001/archinternmed.2007.5 – volume: 6 start-page: e173 issue: 3 year: 2019 ident: pmed.1003101.ref011 article-title: Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study publication-title: Lancet HIV doi: 10.1016/S2352-3018(18)30333-3 – volume: 110 start-page: 215 issue: 4 year: 2017 ident: pmed.1003101.ref006 article-title: Venous thrombotic events in patients admitted to a tuberculosis centre publication-title: QJM – volume: 8 start-page: e022516 issue: 9 year: 2018 ident: pmed.1003101.ref016 article-title: AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile. publication-title: BMJ Open. doi: 10.1136/bmjopen-2018-022516 – volume: 141 start-page: e419S issue: 2 Suppl year: 2012 ident: pmed.1003101.ref020 article-title: Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. publication-title: Chest doi: 10.1378/chest.11-2301 – volume: 347 start-page: f3368 year: 2013 ident: pmed.1003101.ref021 article-title: When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. publication-title: BMJ. doi: 10.1136/bmj.f3368 – ident: pmed.1003101.ref012 – volume: 23 start-page: 1001 issue: 12 year: 2009 ident: pmed.1003101.ref002 article-title: The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy publication-title: AIDS Patient Care STDS doi: 10.1089/apc.2009.0173 – volume: 16 start-page: e1002883 issue: 10 year: 2019 ident: pmed.1003101.ref017 article-title: Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). publication-title: PLoS Med. doi: 10.1371/journal.pmed.1002883 – volume: 104 start-page: 1228 issue: 6 year: 2010 ident: pmed.1003101.ref003 article-title: The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals publication-title: Thromb Haemost |
| SSID | ssj0029090 |
| Score | 2.4487867 |
| Snippet | Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on the risk of... Background Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on... Casper Rokx and colleagues study the risk of recurrent venous thromboembolism in people with HIV infection. BACKGROUND:Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on... Background Multiple studies have described a higher incidence of venous thromboembolism (VTE) in people living with an HIV infection (PWH). However, data on... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e1003101 |
| SubjectTerms | Anticoagulants Antiretroviral drugs Antiretroviral therapy Bacterial infections Biology and Life Sciences Care and treatment CD4 antigen Cell differentiation Cohort analysis Consent Embolism Epidemiology Health aspects Health risk assessment Hematology Highly active antiretroviral therapy HIV HIV infections HIV patients Human immunodeficiency virus Immunodeficiency Infections Infectious diseases Internal medicine Lymphocytes T Medical research Medicine Medicine and Health Sciences Methods Pulmonary embolism Recurrence (Disease) Recurrent infection Risk factors Sensitivity analysis Supervision T cells Thromboembolism Thrombosis |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELegIMQL37DCAIMQPIUljhM3vKCCmDYJChpQ9S2Kv0pEl5SmG_8-d46bEVTBJB76Uv8StXf23fl8_h0hz0ySGAv7hiCzaRJw2EMEkmU8YKqI0lRJkzni-el7MZmMZrPsk0-4Nb6scmMTnaHWtcIc-R5eY-BpIkT0evkjwK5ReLrqW2hcJJewbTbOczE723BlocuxIAtZEDEh_NW5WER7XlMvl-BzsFIAopyo55ocg39npwfLRd1sC0L_rKX8zTntX__fv3WDXPNhKR238-gmuWCqW-TKB3_wfpvIo7L5TmtLV5ifR0YneurYXSn2WTiWtYHPomyOaVlRz9XaUEzy0oPDKd2UfFWv6Ji2-cefpTYU2_Ou1tRx3N4hX_fffXl7EPj2DIESKV8HgqlYS2aZisDRaivVSAgjpIUYTyPvO1emMKHSoijESDEtJHjMdKSs5ZpLEd8lg6quzA6heH1WZ5aFXCXcJlnBQKA8EjGENwYCiiGJN5rJlecuxxYai9wdyAnYw7RyylGfudfnkATdU8uWu-Mf-Deo9A6LzNvui3o1z_1CzlUyQiNWsIIrLk1YsDCTOjQKLB_XDF7yGKdM3l5j7exHPk5jliXYxHFInjoEsm9UWN4zL06aJj_8OD0H6PPkPKCjHuiFB9kaZKYKf-8CJI_UXz3k8x5y3hKfbwPu9oBgkVRveAeXy0bGTX42yeHJzTLYPvykG8aXYgFgZWAyAwa8DUdmpiG51664Tk_IKYm9a4dE9NZiT5H9kar85qjUBUSwPInv__1nPSBXGaZZkLSX75LBenViHpLL6nRdNqtHzub8AuteisI priority: 102 providerName: ProQuest – databaseName: Public Library of Science (PLoS) Journals Open Access dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZQQYgX7rCMAgYheMpIHSdueCuIaZNGmQZUe4t8HdG6pGq68fc5J3EDmToxHvpSf4miY5-b7fMdQt7YJLEO8oYwc2kScsghQsUyHjItR2mqlc0a4vnZgZhOx8fH2eGfRPHSCX4sRu-9THcW4B3wTB_iEch2brIYAm-kdTw86BKsLMoiXx531ZM999Ow9He2eLCYV_WmQPPyfcm_HNDuvf_99Pvkrg816aRdGw_IDVs-JLe_-MP0R0QdFfUprRxd4p47sjTRi4axlWLvhDNVWfjNi_qMFiX1_Ks1xY1burc_o-trXOUHOqHtnuKvwliKLXeXK9rw1j4mP3Y_f_-0F_qWC6EWKV-FgunYKOaYHoHzNE7psRBWKAdxm0Eud66ttJE2Qkox1swIBV4wHWvnuOFKxE_IoKxKu0UolsSazLGI64S7JJMMBMhHIoaQxUKQEJB4PRO59nzk2BZjnjeHbALyklZOOYov9-ILSNg9tWj5OP6B_4iT3GGRTbv5A-Yp98qZ62SMhkkyyTVXNpIsypSJrAZrxg2Dl7zEJZK3pamdTcgnacyyBBszBuR1g0BGjRKv7JzI87rO97_OrgH6Nr0O6KgHeudBrgKZaelrKUDySOfVQ77tIU9aMvNNwGEPCFZG94a3UD3WMq5zLCviaSIESGe4VpnNw6-6YXwpXuorLSxmwIAH4ci2FJCnrYZ184Q8kdiPNiCip3u9ieyPlMXPhh5dQFTKk3j76i9-Ru4w3DZBEl4-JIPV8tw-J7f0xaqoly8am_IbwWR3CA priority: 102 providerName: Public Library of Science |
| Title | Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32407386 https://www.proquest.com/docview/2424465771 https://www.proquest.com/docview/2404045785 https://pubmed.ncbi.nlm.nih.gov/PMC7224453 https://doaj.org/article/c580179a2a4c4be0a209bd0ec7874d21 http://dx.doi.org/10.1371/journal.pmed.1003101 |
| Volume | 17 |
| WOSCitedRecordID | wos000558077100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: 7X7 dateStart: 20041001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: BENPR dateStart: 20041001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: PIMPY dateStart: 20041001 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1549-1676 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029090 issn: 1549-1676 databaseCode: FPL dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELagIMQL4vcCpRiE4Clb4jhxwluHVq3SVqoC1XiKYscZEV1aNd3497lz3GhBlbYHHpKH-Guk3p19Z-fuO0I-6DDUBewb3KSIQpfDHsKVLOEuU5kfRUrqxBDPz0_EZBKfnSXTa62-MCesoQduBHegwhiNJmMZV1xqL2NeInNPK7A0npsScuaJZLuZslutxDOnK8g_5vpMCFs0Fwj_wOpofwXeBnMEIL7xO07JcPe3K3RvtVjWu8LPf7Mor7ml0WPyyMaTdNj8jyfkjq6ekgen9ov5MyJnZf2bLgu6xoN1pGKiV4aWlWKDhAu51HAtyvqClhW1JKs1xdNZejye022uVvWZDmlzcPinzDXFvrrrDTXktM_Jj9HR9y_Hru2r4CoR8Y0rmApyyQqmfPCQeSFVLIQWsoDgLEfCdq50pj2ViywTsWK5kODqolgVBc-5FMEL0quWld4jFOte86RgHlchL0JQE8iD-yKAuERDJOCQYCvYVFnScex9sUjNlzQBm49GTimqI7XqcIjb_mrVkG7cgD9EnbVYpMw2D8CQUmtI6U2G5JC3qPG0qT9tJ346jAKWhNh90SHvDQJpMyrMyznPLus6HX-d3wL0bXIb0KwD-mRBxRJkpjJbMAGSR86uDvJjB3neMJbvAvY7QFhKVGd4D619K-M6xdohHoVCgHT62xmwe_hdO4wvxcy9SoMxAwbcBEdKJYe8bCZMqyckg8Smsw4RnanUUWR3pCp_GQ50AaEnD4NX_0Pzr8lDhqcoyMnL-6S3WV_qN-S-utqU9XpA7oozYe7xgNw7PJpMZwOz2MB9ND2BZ9Px6fTnX7jSgts |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGh4AX7mOFwQzi8pQtcZy4QUKog02t1pWpjGpvIXGcEtElpek28af4jZyTOIGgCvayBx76Un-JWvvcbJ_zHUKeK8dRMewbDC92HYPDHsIImccNJgPLdWWovIJ4fjwQw2Hn-Ng7XCE_qloYTKusbGJhqKNM4hn5NpYxcNcRwno7-2Zg1yi8Xa1aaJRisa--n8OWLX_Tfw_r-4Kxvd2jdz1DdxUwpHD5whBM2lHIYiYt8A9RHMqOEEqEMYQmEdKVc6kCZcpIBIHoSBaJEAy925FxzCMeChvee4WschvMeous7uwOD0f1Fs8zi1Md5D0zLCaELtazhbWtZWNrBl4OcxMgrrIazrDoGVB7htZsmuXLwt4_szd_c4d7t_63ibxNburAm3ZLTblDVlR6l1w70KkF90g4SvKvNIvpHG8gkLOKnhX8tRQ7SZyEmYLPNMlPaJJSzUabUzzGpr3-mFZJbelr2qXlCet5EimKDYjnC1qw-N4nny7lH66RVpqlap1QLBCOvJiZXDo8dryAwQJyS9gQwCkImdrEriTBl5qdHZuETP3iylHALq2cJx_lx9fy0yZG_dSsZCf5B34HhazGIrd48UU2n_jaVPnS6aCZDljAJQ-VGTDTCyNTSbDtPGLwkk0UUb8s1K0tpN91beY52KayTZ4VCOQXSTGBaRKc5rnf_zC-AOjj8CKgUQP0SoPiDOZMBrqyBGYeyc0ayJcN5KSkdl8G3GgAwebKxvA6qmc1x7n_S6ngyUrtlg8_rYfxpZjimCoQZsCAP-XIPdUmD0oNr9cJWTOxO2-biIbuNxayOZImXwqyeAExOnfsh3__WZvkeu_oYOAP-sP9R-QGw0MlpCjmG6S1mJ-qx-SqPFsk-fyJtniUfL5s2_AT36_tcw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELdGhyZe-IYVBjOIj6ewxHHiBgmhwqhWbSvVBtV4Coljl4ouKU23iX-Nv467xAkEVbCXPfDQl_hiNfb5d2f77neEPFGepzTsG6xA-57FYQ9hxSzgFpOR4_syVkFBPD_aE4NB5-goGK6QH1UuDIZVVphYAHWSSTwj38I0Bu57Qjhb2oRFDLd7r2ffLKwghTetVTmNUkV21fcz2L7lr_rbMNdPGeu9-_B2xzIVBiwpfL6wBJNuEjPNpAO2ItGx7AihRKzBTUmQupxLFSlbJiKKREeyRMQA-n5Has0THgsX-r1EVsEl5wAKq8P-_vBTvd0L7OKEBznQLIcJYRL3XPgCoycvZmDxME4BfCynYRiL-gG1lWjNplm-zAX-M5LzN9PYu_Y_D-p1ctU45LRbrqAbZEWlN8navgk5uEXig0n-lWaazvFmArms6GnBa0uxwsRxnCn4TSf5MZ2k1LDU5hSPt-lOf0SrYLf0Je3S8uT1bJIoioWJ5wtasPveJh8v5AvvkFaapWqdUEwcTgLNbC49rr0gYjCZ3BEuOHYKXKk2cSutCKVhbcfiIdOwuIoUsHsrxylEXQqNLrWJVb81K1lL_iH_BhWulkXO8eJBNh-HBsJC6XUQviMWccljZUfMDuLEVhIwnycMOtlEdQ3LBN4aOcOu77LAw_KVbfK4kEDekRSVbRyd5HnYfz86h9Dh4DxCBw2h50ZIZzBmMjIZJzDySHrWkHzWkByXlO_LBDcagoDFstG8jku1GuM8_LXA4M1qCS5vflQ3Y6cY-pgqUGaQATvLkZOqTe6Wq72eJ2TTxKq9bSIaONCYyGZLOvlSkMgL8N255977-9_aJGsACOFef7B7n1xheNaEzMV8g7QW8xP1gFyWp4tJPn9owI-SzxcNDT8ByCv2ZQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+recurrent+venous+thromboembolism+in+patients+with+HIV+infection%3A+A+nationwide+cohort+study&rft.jtitle=PLoS+medicine&rft.au=Rokx%2C+Casper&rft.au=Borjas+Howard%2C+Jaime+F&rft.au=Smit%2C+Colette&rft.au=Wit%2C+Ferdinand+W&rft.date=2020-05-14&rft.pub=Public+Library+of+Science&rft.issn=1549-1277&rft.volume=17&rft.issue=5&rft_id=info:doi/10.1371%2Fjournal.pmed.1003101&rft.externalDocID=A632950589 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |